REGN
Income statement / Annual
Last year (2023), Regeneron Pharmaceuticals, Inc.'s total revenue was $13.12 B,
an increase of 7.76% from the previous year.
In 2023, Regeneron Pharmaceuticals, Inc.'s net income was $3.95 B.
See Regeneron Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$13.12 B
|
$12.17 B
|
$16.07 B
|
$8.50 B
|
$7.86 B
|
$6.71 B
|
$5.87 B
|
$4.86 B
|
$4.10 B
|
$2.82 B
|
| Cost of Revenue |
$1.82 B |
$1.56 B |
$2.44 B |
$1.12 B |
$782.20 M |
$434.10 M |
$397.06 M |
$299.69 M |
$392.71 M |
$205.02 M |
| Gross Profit |
$11.30 B |
$10.61 B |
$13.63 B |
$7.38 B |
$7.08 B |
$6.28 B |
$5.48 B |
$4.56 B |
$3.71 B |
$2.61 B |
| Gross Profit Ratio |
0.86 |
0.87 |
0.85 |
0.87 |
0.9 |
0.94 |
0.93 |
0.94 |
0.9 |
0.93 |
| Research and Development
Expenses |
$4.44 B
|
$3.59 B
|
$2.91 B
|
$2.74 B
|
$3.04 B
|
$2.19 B
|
$2.08 B
|
$2.05 B
|
$1.62 B
|
$1.27 B
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.56 B
|
$1.32 B
|
$1.18 B
|
$838.53 M
|
$504.76 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$2.63 B
|
$2.12 B
|
$1.82 B
|
$1.35 B
|
$1.83 B
|
$1.56 B
|
$1.32 B
|
$1.18 B
|
$838.53 M
|
$504.76 M
|
| Other Expenses |
$184.00 M |
-$89.90 M |
-$45.60 M |
-$280.40 M |
$219.30 M |
$19.10 M |
-$1.08 M |
-$926,000.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$2.82 B |
$5.62 B |
$4.69 B |
$3.80 B |
$4.87 B |
$3.74 B |
$3.40 B |
$3.23 B |
$2.46 B |
$1.78 B |
| Cost And Expenses |
$9.07 B |
$7.18 B |
$7.12 B |
$4.92 B |
$5.65 B |
$4.18 B |
$3.79 B |
$3.53 B |
$2.85 B |
$1.98 B |
| Interest Income |
$495.90 M |
$160.10 M |
$45.80 M |
$18.50 M |
$30.20 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$73.00 M |
$59.40 M |
$57.30 M |
$56.90 M |
$30.20 M |
$28.20 M |
$25.12 M |
$7.20 M |
$14.24 M |
$37.37 M |
| Depreciation &
Amortization |
$421.00 M
|
$341.40 M
|
$286.20 M
|
$235.90 M
|
$210.30 M
|
$148.20 M
|
$145.47 M
|
$104.75 M
|
$74.91 M
|
$52.69 M
|
| EBITDA |
$4.65 B
|
$5.34 B
|
$9.28 B
|
$3.90 B
|
$2.42 B
|
$2.68 B
|
$2.08 B
|
$1.44 B
|
$1.33 B
|
$876.61 M
|
| EBITDA Ratio |
0.35 |
0.42 |
0.58 |
0.46 |
0.28 |
0.38 |
0.35 |
0.27 |
0.31 |
0.3 |
| Operating Income Ratio
|
0.31
|
0.39
|
0.56
|
0.42
|
0.28
|
0.38
|
0.35
|
0.27
|
0.31
|
0.3
|
| Total Other
Income/Expenses Net |
$152.20 M
|
$119.90 M
|
$379.00 M
|
$233.80 M
|
$219.30 M
|
$19.10 M
|
-$1.08 M
|
-$926,000.00
|
-$26.82 M
|
-$62.68 M
|
| Income Before Tax |
$4.20 B |
$4.86 B |
$9.33 B |
$3.81 B |
$2.43 B |
$2.55 B |
$2.08 B |
$1.33 B |
$1.23 B |
$775.75 M |
| Income Before Tax Ratio
|
0.32
|
0.4
|
0.58
|
0.45
|
0.31
|
0.38
|
0.35
|
0.27
|
0.3
|
0.28
|
| Income Tax Expense |
$245.70 M |
$520.40 M |
$1.25 B |
$297.20 M |
$313.30 M |
$109.10 M |
$880.00 M |
$434.29 M |
$589.04 M |
$427.67 M |
| Net Income |
$3.95 B |
$4.34 B |
$8.08 B |
$3.51 B |
$2.12 B |
$2.44 B |
$1.20 B |
$895.52 M |
$636.06 M |
$348.07 M |
| Net Income Ratio |
0.3 |
0.36 |
0.5 |
0.41 |
0.27 |
0.36 |
0.2 |
0.18 |
0.15 |
0.12 |
| EPS |
37.05 |
40.51 |
76.4 |
32.65 |
19.38 |
21.29 |
11.27 |
8.55 |
6.17 |
3.36 |
| EPS Diluted |
34.77 |
38.22 |
71.97 |
30.52 |
18.46 |
21.29 |
10.34 |
7.7 |
5.52 |
2.98 |
| Weighted Average Shares
Out |
$106.70 M
|
$107.10 M
|
$105.70 M
|
$107.60 M
|
$109.20 M
|
$114.80 M
|
$115.90 M
|
$116.25 M
|
$115.23 M
|
$113.41 M
|
| Weighted Average Shares
Out Diluted |
$113.70 M
|
$113.50 M
|
$112.20 M
|
$115.10 M
|
$114.60 M
|
$114.80 M
|
$115.91 M
|
$116.30 M
|
$115.23 M
|
$113.47 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
